Emerging Therapeutics
in Oncology
In this video series, we explore 5 of the most prominent emerging therapeutic modalities in the oncology industry in 2025.
Initial launch date: 1/30/2025
The Foundation: What's Happening, and Why?
The Foundation
Oncology is exploding with new and innovative therapeutics. Let’s slow things down and analyze why this is happening and which technologies are the most promising.
Emerging Therapeutic Modalities
Gene Delivery as Cancer Immunotherapy
As gene therapy as a whole begins to mature as a therapeutic modality in medicine, the strategic delivery of specific genes to stimulate an anti-cancer immune response is becoming a much more popular therapeutic approach in oncology. Watch the full video for the breakdown.
Tumor-Activated Therapeutics
These things are only active inside the tumor due to some kind of biological condition that causes the therapy to change shape and become active.
Radiopharmaceuticals
Radiopharma has exploded in recent years and, if we’re being honest, I think this is the most promising therapeutic on this list. Delivering high-energy radioisotopes directly to cancer cells shreds apart tumors with minimal side effects.
T Cell Engagers for Solid Tumors
Bispecific T cell engagers are making waves in hematological malignancies for their ability to redirect endogenous T cells to cancerous B cells. But, what about solid tumors? Well, these next-gen engagers are promising to deliver.
Next-Gen Targeted Small Molecules
For decades, oncology has been dominated by small molecule therapeutics. However, there are hundreds of protein targets that were thought to be “undruggable” using small molecules…until now.
Course Instructor
Jeff Martin, PhD
Dr. Jeff Martin is a cancer biologist with a PhD in Cancer Genetics and over a decade of experience in immuno-oncology. As the Founder of Oncoleader, Jeff currently advises biotech professionals, providing expert insights on the best ways to navigate the current trends in the immuno-oncology industry.
